Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DQI1F2
|
|||
| Drug Name |
MBL949
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66] | Phase 2 | [1] | |
| Company |
Novartis
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05199090) A Randomized, Placebo-controlled, Participant-and-investigator- Blinded, Sponsor Open-label Study to Evaluate the Safety, Tolerability, and Efficacy With Different Dosing Regimens of Subcutaneously Administered MBL949 in Obese Participants With or Without Type 2 Diabetes Mellitus. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.